- Home
- ZCMD vs QUCY Comparison
ZCMD vs QUCY Comparison
Compare ZCMD & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZCMD | QUCY |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | China | Germany |
| Employees | N/A | 13 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 5.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZCMD | QUCY |
|---|---|---|
| Price | $2.03 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.5K | ★ 324.9K |
| Earning Date | 04-28-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $74.34 |
| Revenue Next Year | N/A | $171.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.40 |
| 52 Week High | $2.10 | $0.74 |
Technical Indicators
Market Signals| Indicator | ZCMD | QUCY |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 39.92 |
| Support Level | $1.09 | $0.42 |
| Resistance Level | N/A | $0.53 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 82.05 | 23.31 |
Price Performance
Historical ComparisonAbout ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About QUCY Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.